Mandate

Vinge advises Acrinova AB (publ) in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Acrinova AB (publ) (“Acrinova” or the “Company”) in connection with the Company’s uplisting to Nasdaq Stockholm. The prospectus was published on 9 December 2022 and trading on Nasdaq Stockholm commenced on 16 December 2022.

Acrinova is a real estate group with a focus on southern Sweden and on commercial properties. The Company offers comprehensive services as owner, manager and developer of real estate. Acrinova has its headquarter in Malmö, Sweden. The Company is uplisting from Nasdaq First North Premier Growth Market, where the Company's shares have been listed since 2019.

Vinge’s team has primarily consisted of Linnéa SellströmEmma Brolund, Lorin Arabi and Michaela Ådén (Capital Markets and Public M&A), as well as Victor Ericsson, Emelie Svanberg and Maja Prahl (Corporate Tax).

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024